Wenlong Lei – Trademark Portfolio
Entity Type: 01
Wenlong Lei owns a portfolio of 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as FYLWIM, LECICI, ZEWAZE, and DADADEER. Of these, 4 are registered and 1 is pending. The portfolio spans 4 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 14 (Jewelry). Headquartered in Ji'an City, Jiangxi.
Futian Town, Qingyuan District,
No. 8, Changjing Village,Beikeng Village
Ji'an City, Jiangxi 343062 , CN
Showing of trademarks Trademarks
Trademark Classifications
Wenlong Lei's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Precious metals and their alloys; jewellery, precious stones; horological instruments
Leather and imitations of leather; animal skins, hides; trunks and travelling bags
Common metals and their alloys; metal building materials; transportable buildings of metal
Frequently Asked Questions
How many trademarks does Wenlong Lei have?
Wenlong Lei has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending.
What trademark classes does Wenlong Lei file in?
Wenlong Lei files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 14 (Jewelry), Class 18 (Leather Goods), Class 6 (Metal Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Wenlong Lei's most well-known trademarks?
Wenlong Lei's registered trademark portfolio includes well-known marks such as FYLWIM, LECICI, ZEWAZE, and DADADEER. These are among 4 currently registered trademarks in the portfolio.
What is Wenlong Lei's trademark registration success rate?
Wenlong Lei has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.